These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15642439)

  • 21. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder.
    Cumming P; Abi-Dargham A; Gründer G
    Behav Brain Res; 2021 Feb; 398():113004. PubMed ID: 33197459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.
    Kessler RM; Ansari MS; Riccardi P; Li R; Jayathilake K; Dawant B; Meltzer HY
    Neuropsychopharmacology; 2006 Sep; 31(9):1991-2001. PubMed ID: 16738543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine D2 receptor imaging and neuroleptic drug response.
    Heinz A; Knable MB; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 11():84-8; discussion 89-93. PubMed ID: 8941175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy.
    Pani L; Pira L; Marchese G
    Eur Psychiatry; 2007 Jul; 22(5):267-75. PubMed ID: 17419008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Visvikis D; Ell PJ; Stephenson C; Kerwin RW; Pilowsky LS
    Br J Psychiatry; 1999 Sep; 175():231-8. PubMed ID: 10645324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential role of lamotrigine in schizophrenia.
    Large CH; Webster EL; Goff DC
    Psychopharmacology (Berl); 2005 Sep; 181(3):415-36. PubMed ID: 16001126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
    Abekawa T; Ito K; Koyama T
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):177-93. PubMed ID: 17103144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent evidence for dopamine abnormalities in schizophrenia.
    Abi-Dargham A
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():341s-347s. PubMed ID: 23573603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the dopamine D2 receptor in schizophrenia.
    Seeman P
    Expert Opin Ther Targets; 2006 Aug; 10(4):515-31. PubMed ID: 16848689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs.
    Lidow MS; Elsworth JD; Goldman-Rakic PS
    J Pharmacol Exp Ther; 1997 Apr; 281(1):597-603. PubMed ID: 9103549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insights into the biology of schizophrenia through the mechanism of action of clozapine.
    Brunello N; Masotto C; Steardo L; Markstein R; Racagni G
    Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.